ScreenerHero

UNCYUnicycive Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · unicycive.com
5.630USD+0.90%Mkt Cap: 154.22M $P/E: —

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a la…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap154.22M $
Enterprise Value91.06M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-26.55M $
Revenue/Share—
Last Price5.630 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)3.90
PEG—
EV/EBITDA-2.75
EV/Revenue—
P/S—
P/B2.85
EPS (TTM)-1.71
EPS (Forward)1.40
52W Range
3.71038% of range8.740
52W High8.740 USD
52W Low3.710 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-87.94%
ROA-54.04%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.32M $
CapEx (TTM)24.00K $
FCF Margin—
FCF Yield-8.25%
Net Debt-60.75M $
Net Debt/EBITDA1.84
Balance Sheet
Debt/Equity0.01
Current Ratio3.81
Quick Ratio3.28
Book Value/Sh1.912 USD
Cash/Share2.205 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJun 20, 2025
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)28.00 USD
Upside (mean)+397.3%
Target Range13.00 USD – 50.00 USD
$13.00+397.3% to mean$50.00
# Analysts9
Ownership
Shares Out.27.39M
Float25.82M
Insiders2.26%
Institutions42.22%
Short Interest
Short Ratio2.0d
Short % Float16.18%
Short % Out.15.81%
Shares Short4.33M
Short (prev mo.)4.67M
Technical
SMA 505.852 (-3.8%)
SMA 2006.398 (-12.0%)
Beta1.78
S&P 52W Chg18.16%
Avg Vol (30d)838.11K
Avg Vol (10d)773.45K
Technical Indicators
RSI (14)53.9
MACD-0.0650
MACD Signal-0.1829
MACD Hist.+0.1180
BB Upper5.733 USD
BB Middle5.233 USD
BB Lower4.732 USD
BB Width19.13%
ATR (14)0.3450 USD
Vol Ratio (20d)1.32x